Navigation Links
External CounterPulsation (ECP) Centers

ProductsExternal CounterPulsation (ECP) Centers
Company MedCath Corporation
Item External CounterPulsation (ECP) Centers
Features ECP Clinical Benefits

Clinical studies have shown that ECP treatment produces improved perfusion of the ischemic myocardium in patients with coronary artery disease. The following patient benefits have been observed:

  • Relief of anginal symptoms
  • Resolution of reversible ischemic defects found upon radio nuclide assessment
  • Improved exercise treadmill times
  • Rectification of exercise ECG ST segment abnormalities
  • No need or reduction of need for anti-anginal medication
  • Improved ability to perform normal activities of daily living
The ACC and Mayo Clinic recently recommended ECP for certain angina patients.
Description Looking for a way to help your patients with chronic angina or end stage cardiovascular disease? Based on the outcomes of several thousand cardiac patients nationwide, External Counterpulsation (ECP) has improved the quality of their lives; it has allowed many to perform normal activities of daily living.

MedCath Diagnostics, LLC, a national provider of cardiac diagnostic services, has assisted physicians with placing this proven cardiac treatment therapy within their office and/or diagnostic centers. We will help with the upfront investment needed to purchase equipment and our development staff will establish a turnkey facility that leaves you free to care for your patients.

Description of Therapy

Patients lie on a bed wearing a series of compressive air cuffs (resembling Blood Pressure cuffs) that are wrapped around the patients legs. The vascular networks in the large muscles of patients legs are compressed in sequence, progressing from the calves upward. Each wave of pressure is electronically synchronized with the patients heartbeat via a microprocessor-interpreted ECG signal, so that the increased blood flow is delivered to the heart at the precise moment of diastole. The result is much higher coronary flow and perfusion as well as increased venous return. Recent studies suggest that ECP promulgates the development of new collaterals to ischemic regions of the myocardium through angiogenesis.

Treatment Course

The recommended regimen is once daily, one-hour treatment, five (5) days a week for seven (7) weeks. Twice daily treatments are an option for some patients, to reduce treatment course duration.

Medicare covers ECP and the reimbursement rates have steadily risen over the past several years. Reimbursement rates for 2003 increased eleven (11) percent from 2000 rates. ECP centers across the country report reimbursement successes with nearly all third party reimbursement payors.

Info MedCath Corporation
Customer Service: (704) 708-6600
Web site: http://www.medcath.com

Related medicine products :

1. The External Neurological Drainage System
2. Monitorr ICP External CSF Drainage and Monitoring System
3. Monitorr ICP External CSF Drainage System
4. EDS 3 CSF External Drainage System
5. Lumbar External Drainage System (LED)
6. External Ventricular Drainage (EVD)
7. Becker External Drainage and Monitoring System
8. Dual-Chamber Model 5388 External (Temporary) Pulse Generator
9. Single-Chamber Model 5348 External (Temporary) Pulse Generator
10. The Hoffmann® II For External Fixation
11. XCaliber External Fixator
... an automated multiplexing platform that uses advanced ... sequence detection and pharmacogenetics applications. Multiple samples ... an open and flexible electronic microarray, the ... all tests sites have been utilized. This ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
... Y Coordinates At The 6 & 9 Oclock ... & 13mm Outer Diameter Radial Axis Marks Cover ... Hand-Held Markers By Mounting The Device To Any ... More Perfect Mark. , ,Etched Calibration Marks ...
... V-shaped bottom allows easy withdrawal of ... pour-out ,• Nesting ring allows easy ... designed for 4, 8, and 12 channel ... permits withdrawal of practically all of the ...
Medicine Products:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... , ... August 19, 2017 , ... ... that it is the first organization with pending recognition status from the Centers ... Program (“DPP”) via group telehealth classes and live video conferencing. , The ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... joined its Orlando location as an interventional pain management physician. He brings a ... the treatment of migraine headaches, and significant experience in spinal cord stimulation for ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport ... a definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: